Pay in 4 interest-free payments of $5.09 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Atherosclerosis 313 , 7075 (2020)
Cotler 7 , Cihan Yurdaydin 8 and Harel Dahari 1 , (1)The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA, (2)Department of Computer Science, Ben-Gurion University, Beer-Sheva, Israel, (3)Department of Software Engineering, Sami Shamoon College of Engineering, Beer-Sheva, Israel, (4)Department of Computer Science, Universite Du QuEbec a MontrEal, MontrEal, Canada, (5)Division of Gastroenterology and Hepatology, Departments of Medicine, Microbiology & Immunology, Stanford School of Medicine, Stanford, California, USA, (6)Translational Hepatology Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, (7)Loyola University Chicago, (8)Department of Gastroenterology and Hepatology, Ko University Medical School , Background: The frequent samples obtained in the LOWR HDV-1 study (Hepatology.2018;67(4):1224-1236) provide a unique opportunity to analyze and mathematically model the interplay among HDV RNA, HBV DNA, and HBsAg during lonafarnib (LNF)-based therapy
Targeted metabolomics analysis shows that 5FU treatment promotes significant changes in metabolite abundance over time (Fig
DOI:10.1200/JCO.2002.07.061 [ Links ] 34
US$ 21.85
US$ 24.14
US$ 24.06
US$ 29.69
US$ 21.38
US$ 26.51
US$ 28.56
US$ 26.77
